EF Hutton analyst Elemer Piros initiated coverage of Monopar Therapeutics with a Buy rating and $24 price target. There are no drugs approved for severe oral mucositis and Monopar "intends to fill the void created by recent drug failures" with its candidate Validive, the firm tells investors. Given its once daily pill formulation, Validive has the potential to capture "very significant market share," if approved, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MNPR:
- Monopar Therapeutics furthers camsirubicin trial past 4th cohort for ASTS
- Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
- Monopar Therapeutics announces MNPR-202 data from ongoing collaboration
- Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
- Monopar Therapeutics resumed with a Buy at Roth Capital